ArticleThe international journal of neuropsychopharmacology2013
Multi-modality: a new approach for the treatment of major depressive disorder.
Article in The international journal of neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Refining Drug Classes: A Multidimensional, Data-Driven Map of Antidepressant Pharmacology.Biological psychiatry global open science · 2026Article
- Pharmacogenetics of antidepressant response: a focused review on CYP2C19, CYP2D6, SLC6A4, and HTR2A polymorphisms.Frontiers in pharmacology · 2026Review
- Microglia-Targeted Nanotherapeutics in Major Depressive Disorder: An Integrative Perspective on Neuroinflammation and Drug Delivery.Pharmaceutics · 2025Review
- A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation.Biochemistry and biophysics reports · 2023Review
- Pathophysiology of Depression: Stingless Bee Honey Promising as an Antidepressant.Molecules (Basel, Switzerland) · 2022Review
- A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment.Neuropsychiatric disease and treatment · 2022Article
- Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice.Neuropsychiatric disease and treatment · 2022Review
- Quercetin and/or Ascorbic Acid Modulatory Effect on Phenobarbital-Induced Sleeping Mice Possibly through GABAPharmaceuticals (Basel, Switzerland) · 2021Article
- The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.Molecular biology reports · 2020Review
- Erinacine A-Enriched Hericium erinaceus Mycelium Produces Antidepressant-Like Effects through Modulating BDNF/PI3K/Akt/GSK-3β Signaling in Mice.International journal of molecular sciences · 2018Article
- Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS.Journal of affective disorders · 2017Article
- New drugs in psychiatry: focus on new pharmacological targets.F1000Research · 2017Review
- Review
- Crystal structures of vortioxetine and its methanol monosolvate.Acta crystallographica. Section E, Crystallographic communications · 2015Article
- Major depressive disorder: mechanism-based prescribing for personalized medicine.Neuropsychiatric disease and treatment · 2015Review
- Ethical and public policy challenges for pharmacogenomics.Dialogues in clinical neuroscience · 2014Review
- Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.CNS drugs · 2014Review
- Vortioxetine: a review of its use in major depressive disorder.CNS drugs · 2014Review
- Vortioxetine: first global approval.Drugs · 2014Article
- Antidepressant combinations: cutting edge psychopharmacology or passing fad?Current psychiatry reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective treatment with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. Several new multi-modal compounds are in development and early results for the most advanced agents indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and transmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.